Back to Search
Start Over
Findings from Henan Province People's Hospital in the Area of Lung Cancer Reported (Foxa1, Induced By Rc48, Regulates Her2 Transcription To Enhance the Tumorigenic Capacity of Lung Cancer Through Pi3k/akt Pathway).
- Source :
- Immunotherapy Weekly; 10/22/2024, p358-358, 1p
- Publication Year :
- 2024
-
Abstract
- A recent study conducted at Henan Province People's Hospital in China explored the role of FOXA1 in regulating HER2 transcription to enhance the tumorigenic capacity of lung cancer through the PI3K/AKT pathway. The research suggests that FOXA1 could potentially serve as a biomarker or therapeutic target in non-small cell lung cancer treatments, with the possibility of the drug Disitamab vedotin (RC48) being a transformative agent in lung cancer therapy. The study highlights the importance of understanding the molecular mechanisms underlying lung cancer progression and the potential for targeted therapies to improve patient outcomes. [Extracted from the article]
- Subjects :
- NON-small-cell lung carcinoma
LUNG tumors
LUNG cancer
LUNG diseases
PI3K/AKT pathway
Subjects
Details
- Language :
- English
- ISSN :
- 10908625
- Database :
- Complementary Index
- Journal :
- Immunotherapy Weekly
- Publication Type :
- Periodical
- Accession number :
- 180340208